Skip to main navigation
Skip to main content
Denali Therapeutics
  • Home
  • Scientific Approach
    • GENETIC PATHWAY POTENTIAL
    • ENGINEERING BRAIN DELIVERY
    • BIOMARKER-DRIVEN DEVELOPMENT
    • PUBLICATIONS
  • Pipeline
  • Patients
  • Investor & Media Relations
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
  • Leadership
  • Partnering
  • Careers
    • Job Openings
    • STEM Outreach Overview
    • Student Internships
    • Postdoc Program
  • Contact

SEC Filings

Sign Up For Updates
Filing date Form Description View
Jun 15, 2018 4 Statement of changes in beneficial ownership of securities View HTML
0001209191-18-038159.pdf
0001209191-18-038159.rtf
Jun 15, 2018 4 Statement of changes in beneficial ownership of securities View HTML
0001209191-18-038158.pdf
0001209191-18-038158.rtf
May 30, 2018 8-K Report of unscheduled material events or corporate event View HTML
0001193125-18-178586.pdf
0001193125-18-178586.rtf
0001193125-18-178586.xls
May 11, 2018 8-K Report of unscheduled material events or corporate event View HTML
0001193125-18-160063.pdf
0001193125-18-160063.rtf
0001193125-18-160063.xls
May 11, 2018 10-Q Quarterly report which provides a continuing view of a company's financial position View HTML
0001193125-18-160070.pdf
0001193125-18-160070.rtf
0001193125-18-160070.xls
May 07, 2018 8-K Report of unscheduled material events or corporate event View HTML
0001193125-18-154519.pdf
0001193125-18-154519.rtf
0001193125-18-154519.xls
Apr 26, 2018 DEF 14A Official notification to shareholders of matters to be brought to a vote ("Proxy") View HTML
0001193125-18-134885.pdf
0001193125-18-134885.rtf
0001193125-18-134885.xls
Apr 26, 2018 DEFA14A Additional proxy soliciting materials - definitive View HTML
0001193125-18-134914.pdf
0001193125-18-134914.rtf
0001193125-18-134914.xls
Apr 11, 2018 4 Statement of changes in beneficial ownership of securities View HTML
0000315066-18-001862.pdf
0000315066-18-001862.rtf
Mar 20, 2018 3 Initial filing by director officer or owner of more than ten percent. View HTML
0001209191-18-020967.pdf
0001209191-18-020967.rtf
Pagination
  • First page «
  • Previous page ‹
  • …
  • Page 63
  • Page 64
  • Current page 65
  • Page 66
  • Page 67
  • …
  • Next page ›
  • Last page »
Displaying 641 - 650 of 719 results

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox


  • Investor & Media Relations

CONTACT US

161 Oyster Point Blvd- South San Francisco, CA 94080

© 2025 Denali Therapeutics

  • Privacy Policy
  • Terms of Use

©2025 Denali Therapeutics | 161 Oyster Point Boulevard, South San Francisco, CA 94080

  • Privacy Policy
  • Terms of Use